Book a Meeting

Online Inquiry

Anti-Glycan Antibody Development Services

Background Production Services Advantages Q&As

Having extensive experience in the field of antibody research, Creative Biolabs is proud to offer our clients a series of anti-carbohydrate antibody development services with the best quality and most competitive price. Aided by our state-of-the-art technology and professional scientists, we are able to help global customers produce anti-carbohydrate antibody, including monoclonal antibody and polyclonal antibody.

Background

Natural antibodies (NAb) are defined as those immunoglobulins (mainly IgM isotype) continuously secreted by B1 type lymphocytes without any previous external antigen stimulation. To date, a broad range of NAb target carbohydrates (NAbC) have been characterized and can be divided into three different groups: 1) conservative NAbC that are practically the same regarding specificity and blood levels in all healthy individuals; 2) alloantibodies to blood group antigens and xenoantibodies to antigens from other species; 3) plastic antibodies, which include antibodies from the two previous groups but with variable levels during certain conditions, such as pregnancy or inflammation. In addition, studies have shown that some NAbCs could react to tumor-associated carbohydrate antigens, which are associated with worse tumor progression.

Plasma-derived anti-glycan antibodies of IgG and IgM isotype bind to polymeric presented Globo H glyco-clusters differentiating healthy controls from ovarian cancer comparable to CA125. Fig.1 Plasma-derived anti-glycan antibodies of IgG and IgM isotype bind to polymeric presented Globo H glyco-clusters differentiating healthy controls from ovarian cancer comparable to CA125. (Pochechueva T, 2017)

Production of Anti-Glycan Antibodies

Recently, many anti-carbohydrate antibodies have been applied in the diagnostic and treatment of tumors. Therefore, there is an urgency to produce more and more antibodies to target various carbohydrate antigens. However, immunization with carbohydrates often leads to a primary IgM response and even no response in some cases as many carbohydrates are self-antigens. In this case, traditional hybridoma technology may have a limitation in the production of anti-carbohydrate antibodies. Based on our advanced hybridoma platform, Creative Biolabs has developed an efficient method of creating anti-carbohydrate monoclonal antibodies by immunizing mice that lack the enzymes to synthesize target glycans. What’s more, our phage display provides another strategy to produce antibodies directed against various carbohydrate moieties since conventional hybridoma technologies have yielded mostly low-affinity antibodies against a limited number of carbohydrate antigens.

Featured Anti-Glycan Antibody Development Services

Equipped with our top antibody production platform, Creative Biolabs is able to offer a full range of anti-carbohydrate antibody production services, which including but not limited to:

Advantages of Our Services

  • High-quality and one-stop service with cost-effective price
  • Comprehensive antibody production platform including phage display and hybridoma
  • Multiple antibody types with high-affinity and specificity
  • Best after-sale service

With extensive experience in antibody generation, Creative Biolabs is confident in offering the best services in a timely and cost-effective manner. Meanwhile, we also provide other services regarding anti-carbohydrate antibody development. For more information, please feel free to contact us.

Reference:

  1. Pochechueva T, et.al. Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. Journal of ovarian research. 2017; 10(1): 8.

Q&As

Q: What are anti-glycan antibodies and why are they important in therapeutic development?
A: Anti-glycan antibodies specifically target glycans on cells and proteins. They are crucial in therapeutic development for detecting and targeting disease-associated glycosylation patterns in conditions like cancer, autoimmune disorders, and infections, enabling precise diagnosis and targeted treatments.
Q: What are the key steps involved in the development of anti-glycan antibodies?
A: Key steps include selecting target glycans, preparing glycan antigens, immunizing host animals, generating hybridoma cells for monoclonal antibodies, screening and characterizing antibodies for specificity and affinity, and scaling up and purifying the selected antibodies for use.
Q: What challenges are associated with anti-glycan antibody development and how are they addressed?
A: Challenges include glycan complexity, poor immunogenicity, and potential cross-reactivity. These are addressed using glycan array screening, synthetic glycan chemistry, and rigorous validation protocols to ensure specificity and efficacy.
Q: How can anti-glycan antibodies be validated for therapeutic use?
A: Validation involves testing antibody specificity, measuring binding strength, assessing biological effects, conducting in vivo studies for efficacy and safety, and following regulatory guidelines for preclinical and clinical testing to ensure safety for human use.
Q: What are the advantages of partnering with a specialized service provider for anti-glycan antibody development?
A: Customization involves an initial consultation to understand objectives, project design with clear milestones, creating tailored glycan antigens, generating and screening antibodies, refining them for optimal performance, and providing ongoing support for successful application in research or therapeutic contexts.
For Research Use Only. Not For Clinical Use.
Related Services:
Contact Info
Phone
  • (USA)
    (UK)
    (Germany)
Fax
Email
ISO 9001 Certified - Creative Biolabs Quality Management System.
Copyright © 2024 Creative Biolabs. All Rights Reserved.